tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Geron price target lowered to $6 from $7 at Wedbush

Wedbush lowered the firm’s price target on Geron (GERN) to $6 from $7 and keeps an Outperform rating on the shares following quarterly results. Based on the firm’s discussion with management, Wedbush believes both a lack of awareness of Rytelo overall, and an apparent wariness of cytopenias associated with Rytelo treatment are key issues for uptake – the firm sees these issues as fixable with recent HCP education efforts.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1